ArticleCurrent medicinal chemistry2026
Molecular Subtypes of Mixed Gastric Cancer Defined by Machine Learning for Predicting Prognosis and Treatment Response.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is traditionally classified into intestinal (IGC), diffuse (DGC), and mixed (MGC) types based on pathological features, with each subtype exhibiting distinct clinical outcomes. Among these, DGC is associated with poor prognosis, characterized by low cell adhesion and a high stromal component. Recent proteomic studies have revealed significant differences in extracellular matrix (ECM) composition between DGC and IGC, highlighting the critical role of ECM in tumor biology. MGC, which combines both intestinal and diffuse characteristics, presents substantial heterogeneity, complicating prognosis and personalized treatment approaches. This study reclassifies MGC using extracellular matrix receptor (ECMR) and cell adhesion (CA)-related genes (ECRGs), closely linked to the biological behavior of DGC, to provide insights into prognosis and treatment response.
methodsRNA sequencing data and clinical information from GC patients were collected from the TCGA and GEO databases, excluding cases of pure IGC and DGC. Based on ECMR and CA-related genes, supervised clustering via non-negative Matrix Factorization (NMF) was used to identify molecular subtypes in MGC. Differential expression and Cox regression analyses were performed to identify prognostic genes, and an ECMR and CA-based gene signature (ECRS) was developed using machine learning techniques. Gene Set Variation Analysis (GSVA) was conducted to assess functional differences between risk groups, while TIDE and pRRophetic analyses were used to predict responses to immunotherapy and chemotherapy.
resultsA total of 239 MGC patients were classified into two molecular subtypes with significant differences in prognosis. Subtype 2 displayed distinct ECM interactions and connective tissue development pathways. To refine the ECRS model, we tested 117 model combinations across 10 machine learning algorithms, selecting the configuration with the best predictive accuracy. This optimized model distinguished biological and immune characteristics between high- and low-risk groups, with low-risk patients showing greater sensitivity to immunotherapy and standard chemotherapy.
conclusionThis study identifies novel molecular subtypes of MGC based on ECMR and CA-related genes and establishes an effective ECRS model to predict prognosis, immunotherapy response, and chemotherapy sensitivity. This model supports personalized treatment strategies for MGC.
Indexed as
Identifiers
40600554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.